Mounjaro and Zepbound: which uses are approved for tirzepatide?

Mounjaro and Zepbound: which uses are approved for tirzepatide?

Mounjaro and Zepbound contain tirzepatide, a medicine that activates the GIP and GLP-1 receptors. A prescription for one of these brands can reflect very different treatment goals. The approved use depends on the country, the condition being treated and, for some indications, the patient’s age or cardiovascular risk. [1] [2] [3]

How the US and European indications differ

In the United States, Mounjaro is approved to improve glucose control in adults and children aged 10 years and older with type 2 diabetes, alongside diet and exercise. In August 2026 the FDA label added reduction of major cardiovascular events in adults with type 2 diabetes who are at high risk. Those events include cardiovascular death, nonfatal heart attack and nonfatal stroke. [1]

The US Zepbound label covers long-term weight management in adults with obesity or adults with overweight and a weight-related condition. It also covers moderate to severe obstructive sleep apnea in adults with obesity. Both indications are accompanied by a reduced-calorie diet and increased physical activity. In the European Union, Mounjaro itself carries an adult weight-management indication: starting BMI of at least 30, or at least 27 with a weight-related condition. [2] [3]

In Egypt, a March 2025 Egyptian Drug Authority notice directed anyone concerned about a Mounjaro pack to a licensed pharmacy or the authority’s hotline, 15301. The notice concerns pack authenticity. Check the Egyptian product leaflet for local indications. [5]

What the weight-loss trial measured

SURMOUNT-1 followed 2,539 adults with overweight or obesity who did not have diabetes. After 72 weeks, average body weight had fallen by 15.0% to 20.9% across the tirzepatide groups and by 3.1% with placebo. These are group averages over a defined treatment period. A person’s medical history, treatment tolerance and follow-up can differ from those of trial participants. [4]

A practical question before surgery

Tirzepatide slows stomach emptying. Because aspiration during general anesthesia or deep sedation has been reported, the US label advises informing the procedure team in advance. Nausea and other gastrointestinal symptoms, current medicines and a personal or family history of medullary thyroid carcinoma are also relevant to the prescribing discussion. The US label contraindicates use in people with that history or with multiple endocrine neoplasia type 2. [1] [2]

What to take into practice

When discussing tirzepatide with a clinician, identify the treatment goal and check whether the local label covers the specific brand, age group and condition.

Sources

Evidence checked on 21 November 2026.

[1] US FDA · Mounjaro prescribing information, indications and warnings (August 2026).

[2] US National Library of Medicine, DailyMed · Zepbound US prescribing information (28 August 2026).

[3] European Medicines Agency · Mounjaro product information, section 4.1 (21 September 2026).

[4] Jastreboff et al. · Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM (2022).

[5] Egyptian Drug Authority. Mounjaro pack authenticity notice / هيئة الدواء المصرية، خطاب توعية بشأن عبوات مونجارو (2025-03).

Leave a Reply

Your email address will not be published. Required fields are makes.

Select your currency
EGP Egyptian pound